The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Open accessAbstract
Objective: Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD) in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects. Methods: Amyloid‐β 1 to 42 peptide (Aβ 1–42), total tau (t‐tau), and tau phosphorylated at the threonine 181 were measured in (1) cerebrospinal fluid (CSF) samples obtained during baseline evaluation of 100 mild AD, 196 mild cognitive impairment, and 114 elderly cognitively normal (NC) subjects in ADNI; and (2) independent 56 autopsy‐confirmed AD cases and 52 age‐matched elderly NCs using a multiplex immunoassay. Detection of an AD CSF profile for t‐tau and Aβ 1–42 in ADNI subjects was achieved using receiver operating characteristic cut points and logistic regression models derived from the autopsy‐confirmed CSF data. Results: CSF Aβ 1–42 was the most sensitive biomarker for AD in the autopsy cohort of CSF samples: receiver operating characteristic area under the curve of 0.913 and sensitivity for AD detection of 96.4%. In the ADNI cohort, a logistic regression model for Aβ 1–42, t‐tau, and APO ε 4 allele count provided the best assessment delineation of mild AD. An AD‐like baseline CSF profile for t‐tau/Aβ 1–42 was detected in 33 of 37 ADNI mild cognitive impairment subjects who converted to probable AD during the first year of the study. Interpretation: The CSF biomarker signature of AD defined by Aβ 1–42 and t‐tau in the autopsy‐confirmed AD cohort and confirmed in the cohort followed in ADNI for 12 months detects mild AD in a large, multisite, prospective clinical investigation, and this signature appears to predict conversion from mild cognitive impairment to AD. Ann Neurol 2009
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A preponderance of evidence supports the interpretation that PIB uptake and CSF Aβ42 are reliable surrogate markers of amyloid plaque pathology in living subjects (15-19).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased concentrations of extracellular soluble phosphorylated tau (p-tau) and total tau (t-tau) constitute a reliable index of this intracellular process in mild cognitive impairment due to AD2,3 and AD dementia.2,4”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredIn the citing paper
“Abnormal CSF Aβ42 values were defined using the previously established cut-off of <192 ng/L57–59.”
From Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity (2017) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Self-citationCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Self-citationMueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.003 · Cited by 1,233
Self-citationFagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897
Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases
Selkoe, D. J. (2004) · Nature Cell Biology · doi:10.1038/ncb1104-1054 · Cited by 863
Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”
The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and, & National Institute on Aging Working Group (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 719
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs
Forman, M. S., Trojanowski, J. Q., & Lee, V. M.-Y. (2004) · Nature Medicine · doi:10.1038/nm1113 · Cited by 715
Self-citationSunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656
Frontotemporal dementia: Clinicopathological correlations
Forman, M. S., Farmer, J., Johnson, J. K., Clark, C. M., Arnold, S. E., Coslett, H. B., Chatterjee, A., Hurtig, H. I., Karlawish, J. H., Rosen, H. J., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20873 · Cited by 478
Self-citationGalasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1016/S1474-4422(03)00530-1 · DOI · Paper page
Cited by
Sorted by citations
Items 401–500 of 1,012
The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans
Kang, J., Korecka, M., Figurski, M., Toledo, J. B., Blennow, K., Zetterberg, H., Waligórska, T., Brylska, M., Fields, L., Shah, N., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.003 · Cited by 100
Self-citationdel Campo, M., Peeters, C. F. W., Johnson, E. C. B., Vermunt, L., Hok-A-Hin, Y. S., van Nee, M., Chen-Plotkin, A., Irwin, D. J., Hu, W. T., Lah, J. J., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00300-1 · Cited by 95
Li, X., & Buxbaum, J. N. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-79 · Cited by 104
Tosun, D., Schuff, N. W., Truran‐Sacrey, D., Shaw, L. M. J., Trojanowski, J. Q., Aisen, P. S. S., Peterson, R., & Weiner, M. W. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.030 · Cited by 99
Self-citationCerebrospinal Fluid Biomarkers for Major Depression Confirm Relevance of Associated Pathophysiology
Ditzen, C., Tang, N., Jastorff, A. M., Teplytska, L., Yassouridis, A., Maccarrone, G., Uhr, M., Bronisch, T., Miller, C. A., Holsboer, F., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.285 · Cited by 98
Schmitz, T. W., Mur, M., Aghourian, M., Bédard, M., & Spreng, R. N. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.001 · Cited by 99
Polygenic hazard score: an enrichment marker for Alzheimer’s associated amyloid and tau deposition
Initiative, A. D. N., Tan, C. H., Fan, C. C., Mormino, E. C., Sugrue, L. P., Broce, I., Hess, C. P., Dillon, W. P., Bonham, L. W., Yokoyama, J. S., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1789-4 · Cited by 95
Self-citationSeshadri, S., Beiser, A., Au, R., Wolf, P. A., Evans, D. A., Wilson, R. S., Petersen, R. C., Knopman, D. S., Rocca, W. A., Kawas, C. H., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.12.002 · Cited by 97
Self-citationAPOEε4 potentiates the relationship between amyloid-β and tau pathologies
Therriault, J., Benedet, A. L., Pascoal, T. A., Mathotaarachchi, S., Savard, M., Chamoun, M., Thomas, E., Kang, M. S., Lussier, F., Tissot, C., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0688-6 · Cited by 105
Self-citationSynergistic interaction between amyloid and tau predicts the progression to dementia
Pascoal, T. A., Mathotaarachchi, S., Shin, M., Benedet, A. L., Mohades, S., Wang, S., Beaudry, T., Kang, M. S., Soucy, J., Labbe, A., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.11.005 · Cited by 101
Ewers, M., Insel, P. A., Jagust, W. J., Shaw, L. M. J., Trojanowski, J. Q., Aisen, P. S. S., Petersen, R. C., Schuff, N. W., Weiner, M. W., & Initiative, A. D. N. (2011) · Cerebral Cortex · doi:10.1093/cercor/bhr271 · Cited by 104
Self-citationPodhorná, J., Krahnke, T., Shear, M. A., Harrison, J., & Initiative, A. D. N. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0170-5 · Cited by 101
Self-citationPhosphorylated Tau as a Candidate Biomarker for Amyotrophic Lateral Sclerosis
Grossman, M., Elman, L., McCluskey, L., McMillan, C. T., Boller, A., Powers, J., Rascovsky, K., Hu, W., Shaw, L., Irwin, D. J., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.6064 · Cited by 94
Self-citationIrwin, D. J., Trojanowski, J. Q., & Grossman, M. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00006 · Cited by 96
Self-citationRaghavan, N., Samtani, M. N., Farnum, M., Yang, E., Novak, G., Grundman, M., Narayan, V., DiBernardo, A., & Initiative, A. D. N. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.05.2187 · Cited by 96
Self-citationMaccecchini, M. L., Chang, M. Y., Pan, C., John, V., Zetterberg, H., & Greig, N. H. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302589 · Cited by 98
Rafii, M. S., Lukic, A. S., Andrews, R. D., Brewer, J. B., Rissman, R. A., Strother, S. C., Wernick, M. N., Pennington, C., Mobley, W. C., Ness, S. L., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170390 · Cited by 99
Self-citationCunningham, E. L., McGuinness, B., McAuley, D. F., Toombs, J., Mawhinney, T., O’Brien, S., Beverland, D., Schott, J. M., Lunn, M. P., Zetterberg, H., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002684 · Cited by 96
Shi, Y., Zu, C., Hong, M., Zhou, L., Wang, L., Wu, X., Zhou, J., Zhang, D., & Wang, Y. (2022) · Pattern Recognition · doi:10.1016/j.patcog.2022.108566 · Cited by 96
Frontotemporal dementia with the V337M MAPT mutation: Tau-PET and pathology correlations
Spina, S., Schonhaut, D. R., Boeve, B. F., Seeley, W. W., Ossenkoppele, R., O'Neil, J. P., Lazaris, A., Rosen, H. J., Boxer, A. L., Perry, D. C., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003636 · Cited by 96
Mitochondrial ATP synthase activity is impaired by suppressed O-GlcNAcylation in Alzheimer's disease
Cha, M.-Y., Cho, H. J., Kim, C., Jung, Y. O., Kang, M. J., Murray, M. E., Hong, H. S., Choi, Y.-J., Choi, H., Kim, D. K., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv358 · Cited by 95
Preoperative cerebrospinal fluid β‐Amyloid/Tau ratio and postoperative delirium
Xie, Z., Swain, C. A., Ward, S. A. P., Zheng, H., Dong, Y., Sunder, N., Burke, D. W., Escobar, D., Zhang, Y., & Marcantonio, E. R. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.58 · Cited by 96
Altered Gray Matter Structural Covariance Networks in Early Stages of Alzheimer's Disease
Montembeault, M., Rouleau, I., Provost, J.-S., & Brambati, S. M. (2015) · Cerebral Cortex · doi:10.1093/cercor/bhv105 · Cited by 94
White matter hyperintensities are associated with disproportionate progressive hippocampal atrophy
Fiford, C. M., Manning, E. N., Bartlett, J. W., Cash, D. M., Malone, I. B., Ridgway, G. R., Lehmann, M., Leung, K. K., Sudre, C. H., Sebastien Ourselin, A., et al. (2016) · Hippocampus · doi:10.1002/hipo.22690 · Cited by 96
Self-citationWeigand, S. D., Vemuri, P., Wiste, H. J., Senjem, M. L., Pankratz, V. S., Aisen, P. S., Weiner, M. W., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.08.230 · Cited by 93
Self-citationConsiderations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
Leuzy, A., Bollack, A., Pellegrino, D., Teunissen, C. E., Joie, R. L., Rabinovici, G. D., Franzmeier, N., Johnson, K. A., Barkhof, F., Shaw, L. M. J., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14528 · Cited by 109
Self-citationChanging Concepts of Alzheimer Disease
McKhann, G. M. (2011) · JAMA · doi:10.1001/jama.2011.810 · Cited by 95
Initiative, T. A. D. N., Zu, C., Jie, B., Liu, M., Chen, S., Shen, D., & Zhang, D. (2016) · Brain Imaging and Behavior · doi:10.1007/s11682-015-9480-7 · Cited by 95
Zhang, Y., Wu, I.-W., Tosun, D., Foster, E., Schuff, N. W., & Initiative, T. P. P. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165540 · Cited by 93
Initiative, T. A. D. N., Zhang, H., Therriault, J., Kang, M. S., Ng, K. P., Pascoal, T. A., Rosa‐Neto, P., & Gauthier, S. G. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0407-6 · Cited by 97
Cerebrovascular disease promotes tau pathology in Alzheimer’s disease
Laing, K. K., Simoes, S., Baena-Caldas, G. P., Lao, P. J., Kothiya, M., Igwe, K. C., Chesebro, A. G., Houck, A. L., Pedraza, L., Hernandez, A. I., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa132 · Cited by 94
Self-citationThe Longitudinal Early‐onset Alzheimer's Disease Study (LEADS): Framework and methodology
Apostolova, L. G., Aisen, P. S. S., Eloyan, A., Fagan, A. M., Fargo, K. N., Foroud, T., Gatsonis, C. A., Grinberg, L. T., Jack, C. R., Kramer, J. H., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12350 · Cited by 93
Self-citationGrothe, M. J., Moscoso, A., Ashton, N. J., Karikari, T. K., Lantero‐Rodriguez, J., Snellman, A., Zetterberg, H., Blennow, K., Schöll, M., & Initiative, A. D. N. (2021) · Neurology · doi:10.1212/wnl.0000000000012513 · Cited by 99
Self-citationHan, M.-R., Schellenberg, G. D., Wang, L.-S., & Initiative, T. A. D. N. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-90 · Cited by 93
Neurocognitive Disorders in DSM-5
Blazer, D. G. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13020179 · Cited by 104
Bendlin, B. B., Carlsson, C. M., Johnson, S. C., Zetterberg, H., Blennow, K., Willette, A. A., Okonkwo, O. C., Sodhi, A., Ries, M. L., Birdsill, A. C., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037720 · Cited by 91
Self-citationIdentifying Changepoints in Biomarkers During the Preclinical Phase of Alzheimer’s Disease
Laurent Younes, B., Albert, M., Moghekar, A., Soldan, A., Pettigrew, C. A., & Miller, M. I. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00074 · Cited by 93
Aβ-induced vulnerability propagates via the brain’s default mode network
Pascoal, T. A., Mathotaarachchi, S. S., Kang, M. S., Mohaddes, S., Shin, M., Park, A. Y., Parent, M. J., Benedet, A. L., Chamoun, M., Therriault, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10217-w · Cited by 90
Spatial navigation—a unique window into physiological and pathological aging
Gažová, I., Vlček, K., Laczó, J., Nedelská, Z., Hynčicová, E., Mokrišová, I., Sheardová, K., & Hort, J. (2012) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2012.00016 · Cited by 99
Zhang, L., Fang, Y., Cheng, X., Lian, Y.-J., & Xu, H.-L. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1299-y · Cited by 88
Steele, N. Z. R., Carr, J. S., Bonham, L. W., Geier, E. G., Damotte, V., Miller, Z. A., Desikan, R. S., Boehme, K. L., Mukherjee, S., Crane, P. K., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002272 · Cited by 91
Kavungal, D., Magalhães, P., Kumar, S. T., Rajasekhar, K., Lashuel, H. A., & Altug, H. (2023) · Science Advances · doi:10.1126/sciadv.adg9644 · Cited by 95
Grossman, M., Powers, J., Ash, S., McMillan, C. T., Burkholder, L., Irwin, D. J., & Trojanowski, J. Q. (2012) · Brain and Language · doi:10.1016/j.bandl.2012.10.005 · Cited by 92
Self-citationEdmonds, E. C., Initiative, A. D. N., Delano‐Wood, L., Jak, A. J., Galasko, D. R., Salmon, D. P., & Bondi, M. W. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150986 · Cited by 98
Self-citationCSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders
Irwin, D. J., Xie, S. X., Coughlin, D. G., Nevler, N., Akhtar, R. S., McMillan, C. T., Lee, E. B., Wolk, D. A., Weintraub, D. A., Chen‐Plotkin, A. S., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005166 · Cited by 94
Self-citationNeuronal injury biomarkers and prognosis in ADNI subjects with normal cognition
Toledo, J. B., Weiner, M. W., Wolk, D. A., Da, X., Chen, K., Arnold, S. E., Jagust, W., Jack, C., Reiman, E. M., Davatzikos, C., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-26 · Cited by 89
Self-citationHu, W. T., Chen‐Plotkin, A. S., Arnold, S. E., Grossman, M., Clark, C. M., Shaw, L. M. J., McCluskey, L. F., Elman, L. B., Karlawish, J. H., Hurtig, H. I., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0723-9 · Cited by 90
Self-citationEitan, E., Thornton‐Wells, T. A., Elgart, K., Erden, E., Gershun, E., Levine, A. A., Volpert, O. V., Azadeh, M., Smith, D. G., & Kapogiannis, D. (2023) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2023.13 · Cited by 97
Cerebrospinal Fluid Aβ to Tau Ratio and Postoperative Cognitive Change
Xie, Z., McAuliffe, S., Swain, C. A., Ward, S. A. P., Crosby, C. A., Zheng, H., Sherman, J. C., Dong, Y., Zhang, Y., Sunder, N., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e318298b077 · Cited by 92
Tau Transgenic Mice as Models for Cerebrospinal Fluid Tau Biomarkers
Barten, D. M., Cadelina, G. W., Hoque, N., DeCarr, L. B., Guss, V. L., Yang, L., Sankaranarayanan, S., Wes, P. D., Flynn, M. E., Meredith, J. E., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110161 · Cited by 94
Targeting Aβ and tau in Alzheimer's disease, an early interim report
Golde, T. E., Petrucelli, L., & Lewis, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.035 · Cited by 89
Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease
The Parkinson Study Group DATATOP Investigators, Zhang, J., Mattison, H. A., Liu, C., Ginghină, C., Auinger, P., McDermott, M., Stewart, T., Kang, U. J., Cain, K. C., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1121-x · Cited by 90
Periventricular hyperintensities are associated with elevated cerebral amyloid
Marnane, M., Al-Jawadi, O., Mortazavi, S. A., Pogorzelec, K. J., Wang, B. W., Feldman, H., Hsiung, G. R., Initiative, A. D. N., Initiative, A. D. N., Weiner, M. W., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002352 · Cited by 91
Self-citationToledo, J. B., Bjerke, M., Da, X., Landau, S. M., Foster, N. L., Jagust, W., Jack, C., Weiner, M., Davatzikos, C., Shaw, L. M., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4829 · Cited by 88
Self-citationVisser, P. J., Reus, L. M., Gobom, J., Jansen, I. E., Dicks, E., van der Lee, S. J., Tsolaki, M., Verhey, F. R. J., Popp, J., Martínez‐Lage, P., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00521-3 · Cited by 92
Self-citationQuantitative structural MRI for early detection of Alzheimer's disease
McEvoy, L. K., & Brewer, J. B. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.162 · Cited by 90
Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples
Watt, A. D., Perez, K. A., Rembach, A., Sherratt, N. A., Hung, L. W., Johanssen, T., McLean, C., Kok, W. M., Hutton, C. A., Fodero‐Tavoletti, M. T., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1083-z · Cited by 88
The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer’s disease
Yassine, H. N., Rawat, V., Mack, W. J., Quinn, J. F., Yurko‐Mauro, K., Bailey‐Hall, E., Aisen, P. S. S., Chui, H. C., & Schneider, L. S. S. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0194-x · Cited by 85
Self-citationApproach to atypical Alzheimer’s disease and case studies of the major subtypes
Dickerson, B. C., McGinnis, S. M., Xia, C., Price, B. H., Atri, A., Murray, M. E., Mendez, M. F., & Wolk, D. A. (2017) · CNS Spectrums · doi:10.1017/s109285291600047x · Cited by 86
Law, L. L., Rol, R. N., Schultz, S. A., Dougherty, R. J., Edwards, D. F., Koscik, R. L., Gallagher, C. L., Carlsson, C. M., Bendlin, B. B., Zetterberg, H., et al. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.01.001 · Cited by 88
Self-citationKitchigina, V. F. (2018) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2018.00036 · Cited by 88
Mitochondrial therapeutic interventions in Alzheimer’s disease
Giau, V. V., An, S. S. A., & Hulme, J. (2018) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2018.09.033 · Cited by 87
DeMarshall, C. A., Nagele, E. P., Sarkar, A., Acharya, N. K., Godsey, G. A., Goldwaser, E. L., Kosciuk, M. C., Thayasivam, U., Han, M. C., Belinka, B. A., et al. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.03.002 · Cited by 88
Self-citationHarari, O., Cruchaga, C., Kauwe, J. S. K., Ainscough, B. J., Bales, K., Pickering, E. H., Bertelsen, S., Fagan, A. M., Holtzman, D. M., Morris, J. C., et al. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.11.032 · Cited by 82
Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative
Weiner, M. W., & Veitch, D. P. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2015.05.007 · Cited by 85
Mattsson, N., Blennow, K., & Zetterberg, H. (2010) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2010.131 · Cited by 86
Self-citationBrody, A. H., & Strittmatter, S. M. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.09.007 · Cited by 89
Pannee, J., Portelius, E., Minthon, L., Gobom, J., Andréasson, U., Zetterberg, H., Hansson, O., & Blennow, K. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13838 · Cited by 85
Self-citationWhite matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease
Soldan, A., Pettigrew, C. A., Zhu, Y., Wang, M., Moghekar, A., Gottesman, R. F., Singh, B., Martinez, O., Fletcher, E. M., DeCarli, C. S., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008864 · Cited by 82
Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative
Laurens, B., Constantinescu, R., Freeman, R. L., Gerhard, A., Jellinger, K. A., Jeromin, A., Krismer, F., Mollenhauer, B., Schlossmacher, M. G., Shaw, L. M. J., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.05.004 · Cited by 87
Self-citationSelective Disruption of the Cerebral Neocortex in Alzheimer's Disease
Desikan, R. S., Sabuncu, M. R., Schmansky, N. J., Reuter, M., Cabral, H., Hess, C. P., Weiner, M. W., Biffi, A., Anderson, C. D., Rosand, J. M., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012853 · Cited by 83
Prediction of Alzheimer's disease pathophysiology based on cortical thickness patterns
Hwang, J., Kim, C. M., Jeon, S., Lee, J. M., Hong, Y. J., Roh, J. H., Lee, J., Koh, J., Na, D. L., & Initiative, A. D. N. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.11.008 · Cited by 87
Self-citationUnbiased comparison of sample size estimates from longitudinal structural measures in ADNI
Holland, D., McEvoy, L. K., Dale, A. M., & Initiative, T. A. D. N. (2011) · Human Brain Mapping · doi:10.1002/hbm.21386 · Cited by 85
Word-list intrusion errors predict progression to mild cognitive impairment.
Thomas, K. R., Initiative*, T. A. D. N., Eppig, J. S., Edmonds, E. C., Jacobs, D. M., Libon, D. J., Au, R., Salmon, D. P., & Bondi, M. W. (2018) · Neuropsychology · doi:10.1037/neu0000413 · Cited by 89
Initiative, A. D. N., Huang, K., Lin, Y., Yang, L., Wang, Y., Cai, S., Pang, L., Wu, X., & Huang, L. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0551-0 · Cited by 85
Self-citationHeterogeneous cortical atrophy patterns in MCI not captured by conventional diagnostic criteria
Edmonds, E. C., Eppig, J. S., Bondi, M. W., Leyden, K. M., Goodwin, B., Delano‐Wood, L., McDonald, C. R., & Initiative, A. D. N. (2016) · Neurology · doi:10.1212/wnl.0000000000003326 · Cited by 87
Self-citationSchwarz, C. G., Senjem, M. L., Gunter, J. L., Tosakulwong, N., Weigand, S. D., Kemp, B. J., Spychalla, A. J., Vemuri, P., Petersen, R. C., Lowe, V. J., et al. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.08.056 · Cited by 83
Self-citationDevelopment and validation of language and visuospatial composite scores in ADNI
Choi, S., Mukherjee, S., Gibbons, L. E., Sanders, R. E., Jones, R. N., Tommet, D., Mez, J., Trittschuh, E. H., Saykin, A. J., Lamar, M., et al. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12072 · Cited by 83
Self-citationLongitudinal neuroanatomical and cognitive progression of posterior cortical atrophy
Firth, N. C., Primativo, S., Marinescu, R. V., Shakespeare, T. J., Gonzalez, A. S., Lehmann, M., Carton, A. M., Ocal, D., Pavisic, I. M., Paterson, R. W., et al. (2019) · Brain · doi:10.1093/brain/awz136 · Cited by 83
Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts
Scheltens, N. M. E., Tijms, B. M., Koene, T., Barkhof, F., Teunissen, C. E., Wolfsgruber, S., Wagner, M., Kornhuber, J., Peters, O., Cohn‐Sheehy, B. I., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.03.002 · Cited by 82
Johnstone, D. M., Milward, E. A., Berretta, R. E., Moscato, P., & Initiative, A. D. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034341 · Cited by 83
Self-citationBiomarkers in Alzheimer's disease with a special emphasis on event-related oscillatory responses
Yener, G., & Başar, E. (2013) · Supplements to Clinical neurophysiology · doi:10.1016/b978-0-7020-5307-8.00020-x · Cited by 84
Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI
Vos, S. J. B., van Rossum, I., Burns, L. C., Knol, D. L., Scheltens, P., Soininen, H. S., Wahlund, L., Hampel, H. J., Tsolaki, M., Minthon, L., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.017 · Cited by 82
Self-citationFinding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity
Jutten, R. J., Sikkes, S. A. M., van der Flier, W. M., Scheltens, P., Visser, P. J., Tijms, B. M., & Initiative, A. D. N. (2021) · Neurology · doi:10.1212/wnl.0000000000012022 · Cited by 82
Self-citationEvidence that iron accelerates Alzheimer’s pathology: a CSF biomarker study
Ayton, S., Diouf, I., & Bush, A. I. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316551 · Cited by 86
The Role of Clusterin in Amyloid-β–Associated Neurodegeneration
Desikan, R. S., Thompson, W. K., Holland, D., Hess, C. P., Brewer, J. B., Zetterberg, H., Blennow, K., Andreassen, O. A., McEvoy, L. K., Hyman, B. T., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4560 · Cited by 79
Self-citationSuspected non-AD pathology in mild cognitive impairment
Wisse, L. E. M., Butala, N., Das, S. R., Davatzikos, C., Dickerson, B. C., Vaishnavi, S. N., Yushkevich, P. A., & Wolk, D. A. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.029 · Cited by 78
Chételat, G., Ossenkoppele, R., Villemagne, V. L., Perrotin, A., Landeau, B., Mézenge, F., Jagust, W. J., Dore, V., Miller, B. L., Egret, S., et al. (2016) · Brain · doi:10.1093/brain/aww159 · Cited by 80
Brain Entropy Mapping in Healthy Aging and Alzheimer’s Disease
Wang, Z., & Initiative, A. D. N. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.596122 · Cited by 78
Self-citationWhite matter hyperintensities and their relationship to cognition: Effects of segmentation algorithm
Tubi, M. A., Feingold, F. W., Kothapalli, D., Hare, E. T., King, K. S., Thompson, P. M., & Braskie, M. N. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.116327 · Cited by 76
Moodley, K. K., Minati, L., Contarino, V. E., Prioni, S., Wood, R., Cooper, R., D’Incerti, L., Tagliavini, F., & Chan, D. (2015) · Hippocampus · doi:10.1002/hipo.22417 · Cited by 79
The corticobasal syndrome–Alzheimer’s disease conundrum
Hassan, A., Whitwell, J. L., & Josephs, K. A. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.153 · Cited by 80
González‐Martínez, Á., Rosado, B., Pesini, P., Suarez, M. L., Santamarina, G., García‐Belenguer, S., Villegas, A., Monleón, I., & Sarasa, M. (2011) · Experimental Gerontology · doi:10.1016/j.exger.2011.02.013 · Cited by 85
Dorey, A., Tholance, Y., Vighetto, A., Perret‐Liaudet, A., Lachman, I., Krolak‐Salmon, P., Wagner, U., Struyfs, H., Deyn, P. P. D., Elmoualij, B., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4068 · Cited by 84
Laforce, R., & Rabinovici, G. D. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt93 · Cited by 79
Nathan, P. J., Lim, Y. Y., Abbott, R., Galluzzi, S., Marizzoni, M., Babiloni, C., Albani, D., Bartrés‐Faz, D., Didic, M., Farotti, L., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.01.013 · Cited by 82
Maternal family history is associated with Alzheimer's disease biomarkers
Honea, R. A., Initiative, F. T. A. D. N., Vidoni, E. D., Swerdlow, R. H., & Burns, J. M. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120676 · Cited by 79
Self-citationThe A/T/N biomarker scheme and patterns of brain atrophy assessed in mild cognitive impairment
Ekman, U., Ferreira, D., & Westman, E. (2018) · Scientific Reports · doi:10.1038/s41598-018-26151-8 · Cited by 79
Weiner, M. W., Veitch, D. P., Hayes, J., Neylan, T. C., Grafman, J. H., Aisen, P. S. S., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.04.005 · Cited by 81
Self-citationMattsson, N., Zegers, I., Andréasson, U., Bjerke, M., Blankenstein, M. A., Bowser, R. P., Carrillo, M. C., Gobom, J., Heath, T., Jenkins, R. G., et al. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.39 · Cited by 79
Self-citation
Metadata
- Authors
- Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., Dean, R., Siemers, E., Potter, W., Lee, V. M. ‐., Trojanowski, J. Q., & Initiative, A. D. N.
- Affiliations
- University of Pennsylvania (US)
- Fujirebio (Belgium) (BE)
- University of California San Diego (US)
- Mayo Clinic (US)
- University of Gothenburg (SE)
- Pfizer (United States) (US)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Eli Lilly (United States) (US)
- Corresponding author
- Shaw, Leslie M.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2009-04
- Volume
- 65
- Issue
- 4
- Pages
- 403-413
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC2696350
- OpenAlex
- W2008301592
- Cited by
- 2,065
- References
- 31
- Citations by year
- 2026: 59 · 2025: 82 · 2024: 110 · 2023: 89 · 2022: 114 · 2021: 125 · 2020: 136 · 2019: 141 · 2018: 129 · 2017: 135 · 2016: 121 · 2015: 146 · 2014: 131 · 2013: 130 · 2012: 136
- FWCI
- 85.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Pennsylvania
- National Institutes of Health (5u01ag024904-10)
- National Institute on Aging (U01-AG-024904, AG 024904, P30AG010124, AG-10124, U19AG010483, U19AG024904)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid-beta 42, total tau, mild cognitive impairment, conversion to Alzheimer's disease, APOE ε4, Alzheimer's Disease Neuroimaging Initiative
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cognition Disorders, Diagnostic Imaging, Female, Humans, Male, Middle Aged, Peptide Fragments, Phosphorylation, Retrospective Studies, ROC Curve, Sensitivity and Specificity, Threonine, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Disease Progression, Statistics, Nonparametric, Area Under Curve, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
